B of A Securities Downgrades Amphastar Pharmaceuticals to 'Sell'
Amphastar Pharmaceuticals received a 'sell' rating from B of A Securities with a $20 price target, a 1.04% downside from the current price.
Key Points
- B of A Securities downgraded Amphastar Pharmaceuticals to a 'sell' with a $20 price target on June 29, 2026.
- B of A Securities's $20 price target implies 1.04% downside from Amphastar Pharmaceuticals, Inc.'s ($AMPH) current $20.21 share price.
- Shares of Amphastar Pharmaceuticals traded near $20.21 on Wednesday, with a market cap of about $889.8 million.
- BlackRock reduced its Amphastar holdings by 40,672 shares, while Vanguard opened a new position with 1,543,655 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 29, 2026, B of A Securities analyst Jason Gerberry downgraded Amphastar Pharmaceuticals, Inc. (NasdaqGS: AMPH) to a 'sell' rating, setting a price target of $20. This move comes as the stock traded near $20.21 on Wednesday.
B of A Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Amphastar Pharmaceuticals, Inc. Stock Down 8.2%
Shares of NasdaqGS:AMPH traded close to $20.21 on Wednesday. Amphastar Pharmaceuticals has a market capitalization of approximately $889.8 million. The stock's P/E ratio stands at 12.2, with a forward P/E of 6.6, and it has a beta of 0.902, indicating moderate volatility. Over the past year, the stock has ranged from a low of $16.65 to a high of $31.26. Its 50-day moving average is $20.02, while the 200-day moving average is $23.77. The company maintains a strong financial position with a current ratio of 3.85 and a quick ratio of 2.73, although it has a higher debt-to-equity ratio of 88.75.
$AMPH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
For the most recent period, Amphastar Pharmaceuticals reported revenue of $720.5 million, experiencing a slight revenue growth of 0.4%. The company's net margin is 11.0%, and it achieved a return on equity of 10.4%. The next earnings report is scheduled for August 6, 2026.
Other Institutional Activity in Amphastar Pharmaceuticals
Several institutional investors have adjusted their positions in Amphastar Pharmaceuticals. BlackRock, Inc. trimmed its holdings by 40,672 shares, bringing its total to 5,421,343 shares valued at approximately $106.2 million. Dimensional Fund Advisors LP increased its position by 228,262 shares, holding 2,027,947 shares worth about $39.7 million, reflecting a 12.7% increase. State Street Corp added 75,729 shares, now holding 1,607,515 shares valued at around $31.5 million, marking a 4.9% increase. Vanguard Capital Management LLC opened a new position, acquiring 1,543,655 shares valued at roughly $30.2 million. Meanwhile, TD Asset Management Inc. reduced its stake by 422,008 shares, ending with 1,541,044 shares valued at approximately $30.2 million, representing a 21.5% decrease.
Insider Buying and Selling at Amphastar Pharmaceuticals, Inc.
Recent insider activity at Amphastar Pharmaceuticals includes several transactions on June 1, 2026. Richard Prins, Michael Zasloff, Diane Gerst, Gayle Deflin, and David Russell Gaugh each purchased 8,143 shares, while Lee Howard sold 769 shares at an average price of $18.45 on June 2, 2026.
Analysts Set New Price Targets
On June 29, 2026, B of A Securities downgraded Amphastar to a 'sell' with a $20 price target. Barclays maintained its 'hold' rating with a $20 target on June 3, 2026. Wells Fargo downgraded the stock to 'hold' with a $19 target on May 14, 2026. Piper Sandler reiterated a 'hold' rating with a $21 target on May 11, 2026. Overall, the consensus among analysts is a 'hold' with an average price target of $22, based on six analyst opinions.
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company based in Rancho Cucamonga, California. It develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal products. The company serves markets in the United States, China, and France. Amphastar offers a range of products, including treatments for hypoglycemia, asthma, and opioid overdose, among others. Dr. Yongfeng Zhang is the CEO, and the company employs approximately 1,976 people.
Bottom Line
B of A Securities' downgrade of Amphastar Pharmaceuticals to a 'sell' reflects a cautious stance on the company's prospects, with a price target of $20. Investors should note that analyst ratings are one of many factors to consider when evaluating stock performance. The stock has shown moderate volatility and maintains a solid financial position, but the outlook remains mixed among analysts.
Get Amphastar Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AMPH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.